AP 3.2 Hochdurchsatzanalytik für den Schnellnachweis von Krebserkrankungen

Ziele

• Isolation von zellfreier DNA
• DNA-Modifikation
• Amplifikation der Targetsequenzen
• Entwicklung eines digitalen Nachweisverfahrens

Wissenschaftler: Dr. Markus Friedemann
PI: Prof. Mario Menschikowski
Institut für Klinische Chemie und Laboratoriumsmedizin (IKL), TU Dresden

Publications

Friedemann, M. et al. Blood-Based DNA Methylation Analysis by Multiplexed OBBPA-ddPCR to Verify Indications for Prostate Biopsies in Suspected Prostate Cancer Patients. Cancers 16; 10.3390/cancers16071324 (2024).
Friedemann, M. et al. Increased Sensitivity of Detection of RASSF1A and GSTP1 DNA Fragments in Serum of Prostate Cancer Patients: Optimisation of Diagnostics Using OBBPA-ddPCR. Cancers 13; 10.3390/cancers13174459 (2021).
Friedemann, M. et al. Methylation of the Phospholipase A2 Receptor 1 Promoter Region in Childhood B Cell Acute Lymphoblastic Leukaemia. Scientific reports 10, 9058; 10.1038/s41598-020-65825-0 (2020).
Friedemann, M. et al. Instructing Human Macrophage Polarization by Stiffness and Glycosaminoglycan Functionalization in 3D Collagen Networks. Advanced healthcare materials 6; 10.1002/adhm.201600967 (2017).